Conference Correspondent

Conference Correspondent

Omadacycline is a new intravenous/oral antibiotic for patients presenting in the emergency department with acute bacterial skin and soft tissue infections.
The randomized, controlled Omadacycline in Acute Skin Structure Infections Study (OASIS)-2 study comparing omadacycline and linezolid for the treatment of adults with an acute bacterial skin and skin structure infection (ABSSSI) that is known or suspected to result from a gram-positive pathogen enrolled 735 patients, with 368 and 367 patients in each group, respectively.
Investigators evaluated the in vitro activity of omadacycline, a novel aminomethylcycline antibiotic, against a collection of clinical isolates resistant to other available tetracyclines.
A pooled analysis showed favorable safety results from phase 3 studies of omadacycline, a new once-daily intravenous/oral therapy for the monotherapy of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
Pooled safety data of eravacycline in 3 comparator-controlled studies for the treatment of complicated intra-abdominal infections showed that it was generally well-tolerated compared with ertapenem and meropenem.
A pooled analysis showed favorable safety results from phase 3 studies of omadacycline, a new once-daily intravenous/oral therapy for the monotherapy of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
Identifying social vulnerabilities that likely impact pediatric outpatient antimicrobial treatment after discharge could better enable treatment customization or prompt care coordination.
A protocol to guide rational antibiotic therapy in patients receiving extracorporeal membrane oxygenation can lead to a reduction in the use of specific antibiotics, but paradoxically, may increase overall antibiotic use.
In patients with community-acquired pneumonia, a regimen that includes a fluoroquinolone (and possibly a macrolide) may reduce mortality compared with beta-lactams (with or without a beta-lactamase inhibitor) and cephalosporins alone.
Evaluation of lefamulin, a novel oral antimicrobial, in patients with community-acquired bacterial pneumonia demonstrated noninferiority for both the US Food and Drug Administration and European Medicines Agency efficacy end points versus oral moxifloxacin.
Page 1 of 11
Results 1 - 10 of 103
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME